Setiwalidi Kaidiriye, Li Yimeng, Ma Yuyan, Hao Zhanpeng, Zhao Yujia, Zhang Yuxin, Liang Xuan, Tian Tao, Ruan Zhiping, Yao Yu, Fu Xiao
Department of Medical Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Front Oncol. 2024 Nov 19;14:1431908. doi: 10.3389/fonc.2024.1431908. eCollection 2024.
Pralsetinib and selpercatinib have been approved as specific tyrosine kinase inhibitors (TKIs) for the treatment of patients with non-small cell lung cancer (NSCLC) harboring rearranged during transfection () fusion and mutation. However, adverse events associated with pralsetinib and selpercatinib are not fully understood, especially in the real world. In this case, invasive aspergillosis that appeared concurrent with RET-TKI targeted therapy is proposed to be an additional adverse drug reaction (ADR) that was not mentioned in previous reports. Here, we describe the process of clinical diagnosis and treatment of invasive aspergillosis and attempt to explore its possible pathogenesis in association with RET-TKI targeted therapy, with the aim of providing clinicians a more in-depth understanding of the ADR associated with RET-TKIs, as well as to prevent serious outcomes caused by reduction or discontinuation of antitumor therapy.
普拉替尼和塞尔帕替尼已被批准作为特异性酪氨酸激酶抑制剂（TKIs），用于治疗携带转染重排（RET）融合和突变的非小细胞肺癌（NSCLC）患者。然而，与普拉替尼和塞尔帕替尼相关的不良事件尚未完全明确，尤其是在现实世界中。在本病例中，与RET-TKI靶向治疗同时出现的侵袭性曲霉病被认为是一种先前报告中未提及的额外药物不良反应（ADR）。在此，我们描述侵袭性曲霉病的临床诊断和治疗过程，并试图探讨其与RET-TKI靶向治疗相关的可能发病机制，旨在让临床医生更深入地了解与RET-TKIs相关的ADR，以及预防因抗肿瘤治疗减量或停药导致的严重后果。
